APA (7th ed.) Citation

HJ, L., R, R., J, F., J, M., IW, F., JM, B., . . . CA, Y. (2025). Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood, 145(3), 290. https://doi.org/10.1182/blood.2024024681

Chicago Style (17th ed.) Citation

HJ, Lee, et al. "Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-stage Classical Hodgkin Lymphoma." Blood 145, no. 3 (2025): 290. https://doi.org/10.1182/blood.2024024681.

MLA (9th ed.) Citation

HJ, Lee, et al. "Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-stage Classical Hodgkin Lymphoma." Blood, vol. 145, no. 3, 2025, p. 290, https://doi.org/10.1182/blood.2024024681.